Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis

American Journal of Respiratory and Critical Care Medicine

Volumn 149, Issue 6, 1994, Pages 1583-1590

  Wells, Athol U ^a   Cullinan, Paul ^a   Hansell, David M ^a   Rubens, Michael B ^a   Black, Carol M ^a   Newman Taylor, Anthony J ^a   Du Bois, Roland M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DISEASE ASSOCIATION; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SURVIVAL; SYSTEMIC SCLEROSIS;

EID: 0028360565     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.149.6.8004317     Document Type: Article

References (45)

1. Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972;27:535-42.
2. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978;298:801-9.
3. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis; clinical features and their influence on survival. Thorax 1980; 35:171-80.
4. Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983;38:349-55.
5. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 1976;85:769-88.
6. Weaver AL, Divertie MB, Titus JL. Pulmonary scleroderma. Dis Chest 1968;54:4-12.
7. LeRoy EC. Sentinel signs and symptoms of systemic sclerosis. Curr Opin Rheumatol 1989;1:499-504.
8. Harrison NK, Myers R, Corrin B, Soosay G, Dewar A, Black CM, du Bois RM, Turner-Warwick M. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144:706-13.
9. Bergin CJ, Muller NL. CT of interstitial lung disease: a diagnostic approach. AJR 1987;148:8-15.
10. Haslam PL, Turton CWG, Lukoszek A, Salsbury AJ, Dewar A, Collins JV, Turner-Warwick M. Bronchoalveolar lavage fluid cell counts in cryptocgenic fibrosing alveolitis and their relation to therapy. Thorax 1980;35: 328-39.
11. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124:1-8.
12. Hay FG, Turner-Warwick M. Cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis): review of certain features leading to new areas of investigation. In: Flenley DC, Petty TL, eds. Recent advances in respiratory medicine. Edinburgh: Churchill Livingston, 1986;131-51.
13. Peters-Golden M, Wise RA, Hochberg MC, Stevens MB, Wigley FM. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984;77:1027-34.
14. Schneider PD, Wise RA, Hochberg MC, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med 1982;73:385-94.
15. Greenwald GI, Tashkin DP, Gong H, Simmons M, Duann S, Furst DE, Clements P. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study. Am J Med 1987;83:83-91.
16. Bagg LR, Hughes DTD. Serial pulmonary function tests in progressive systemic sclerosis. Thorax 1979;34:224-8.
17. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985;28:882-8.
18. Agusti C, Xaubet A, Roca J, Agusti AGN, Rodriguez-Roisin R. Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 1992;47:1035-40.
19. Colp CR, Riker J, Williams MH. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med 1973;132:506-15.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
21. Quanjer PH. Standardised lung function testing. Clin Respir Physiol 1983;19(Suppl 5:1-95).
22. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97-103.
23. Collins CD, Wells AU, Morgan RA, MacSweeney JE, du Bois RM, Rubens MB, Hansell DM. Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography. Clin Rad 1994;49:236-40.
24. Muller NL, Mawson JB, Mathieson JR, Abboud R, Ostrow DN, Champion N. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989;171:613-8.
25. Aberle DR, Hansell DM, Brown K, Tashkin DP. Lymphangiomyomatosis: CT, chest radiographic and functional correlations. Radiology 1990; 176:381-7.
26. Muller NL, Miller RR, Webb WR, Evans KG, Ostrow DN. Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986;160:585-8.
27. Muller NL, Staples CA, Miller RR, Vedal S, Thurlbeck WM, Ostrow DN. Disease activity in Idiopathic pulmonary fibrosis: CT and pathological correlation. Radiology 1987;165:731-4.
28. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, du Bois RM. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992;47:738-42.
29. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM. The predictive value of appearances on thin section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993;148:1076-82.
30. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall Ltd., 1988.
31. 99mTc-DTPA clearance. Respir Med 1989;83:403-14.
32. Keogh BA, Crystal RG. Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 1980;78:856-64.
33. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990;84:365-9.
34. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978;64:998-1004.
35. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-9.
36. Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Polzleitner D, Burghuber OC, Tscholakoff D. Interstitial lung disease in progressive systemic sclerosis: high resolution CT versus radiography. Radiology 1990;176:755-9.
37. Bergin C, Muller N, Nichols DM, Lillington G, Hogg JC, Mullen B, Grymaloski MR, Osborne S, Pare PD. The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986;137:321-5.
38. Turner-Warwick M, Lebowicz M, Borrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980;35:496-9.
39. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984;63:221-31.
40. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Derbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-8.
41. Meier-Sydow J, Rust M, Kronenberger H, Thiel C, Amthor M, Reimann H. Long term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with azathioprine, D-penicillamine or prednisolone. Prax Klin Pneumol 1979;33:680-9.
42. Raghu G, Depaso WJ, Cain K, Hammer SP, Wetzet CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6.
43. Owens GR, Paradis IL, Gryzan S, Medsger TA, Follansbee WP, Klein HA, Dauber JH. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. J Lab Clin Med 1986;107:253-9.
44. 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993;6:897-902.
45. Southcott AM, Jones KP, Pantelidis P, Black CM, Davies BH, du Bois RM. Interleukin-8 is associated with the presence of pulmonary fibrosis in systemic sclerosis (abstract). Am Rev Respir Dis 1993;147:A755.